A Study to Investigate Efficacy and Safety of KBL697 in Patients With Moderate Plaque Type Psoriasis

• Status: Not yet recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: KoBioLabs

Criteria

Inclusion Criteria:

• Male or female, aged 18 to 75 years (inclusive)

• Have a diagnosis of plaque type psoriasis for ≥ 6 months

• Must have chronic plaque type psoriasis of moderate severity

• All subjects must agree and commit to the use of a reliable contraceptive regimen.

Exclusion Criteria:

• Current diagnosis of forms of psoriasis other than chronic plaque type only

• Drug-induced psoriasis

• Other inflammatory skin disease that may confound the evaluation of plaque psoriasis

• Failed 2 or more systemic treatments for plaque psoriasis

• Medicinal shampoos that contain tar and/or salicylic acid within 2 weeks prior to Baseline Visit